Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Stephanie Parish

Nurse Practitioner, Psychiatric/Mental Health Searcy, AR Nurse Practitioner

NPI 1457076853 CMS profile 11413915

2908 Hawkins Dr, Searcy, AR 72143

Open in the dashboard

General payments

$8,530

414 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephanie Parish of Searcy, AR is reported in the CMS Open Payments database as having received $8,530 across 414 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,711 156
2024 General $2,703 126
2023 General $2,809 118
2022 General $306 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephanie Parish
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Stephanie Parish were reported at $2,711. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Stephanie Parish Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $166 $54–$482 $132
2022 $306 $195 $66–$559 $149
2023 $2,809 $233 $82–$673 $160
2024 $2,703 $236 $84–$688 $164
2025 $2,711 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $2,509 108 payments
  2. ITI, Inc. $1,179 54 payments
  3. Otsuka America Pharmaceutical, Inc. $1,026 51 payments
  4. Neurocrine Biosciences, Inc. $812 37 payments
  5. Janssen Pharmaceuticals, Inc $745 35 payments
  6. Teva Pharmaceuticals USA, Inc. $468 28 payments
  7. Lundbeck LLC $458 28 payments
  8. Alkermes, Inc. $354 24 payments
  9. Vanda Pharmaceuticals Inc. $189 13 payments
  10. Axsome Therapeutics, Inc. $175 8 payments
  11. Other $615 28 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $8,441 413 payments
  2. Education $89 1 payment
Products named General payments · program years 2022–2025
  1. VRAYLAR Neuroscience $1,873 71 payments
  2. CAPLYTA Psychiatry $831 36 payments
  3. INGREZZA $770 36 payments
  4. INVEGA SUSTENNA $670 32 payments
  5. VRAYLAR Neuroscience $608 36 payments
  6. REXULTI Psychiatry $458 28 payments
  7. ABILIFY ASIMTUFII $445 21 payments
  8. ABILIFY MAINTENA $365 17 payments
  9. CAPLYTA Psychiatry $348 18 payments
  10. REXULTI Psychiatry $342 19 payments
  11. Other $3,350 205 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

4,467

Median for Nurse Practitioner: 389

Drug cost

$406,264

Median for Nurse Practitioner: $21,885

Branded share of claims

12.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 46 $126,817
Caplyta Lumateperone Tosylate Brand 46 $77,235
Vraylar Cariprazine Hcl Brand 45 $66,324
Fanapt Iloperidone Brand 12 $40,610
Aripiprazole Generic 197 $20,473
Trintellix Vortioxetine Hydrobromide Brand 19 $9,382
Belsomra Suvorexant Brand 18 $7,722
Duloxetine Hcl Generic 337 $6,577
Quetiapine Fumarate Generic 342 $6,096
Hydroxyzine Hcl Generic 153 $4,022

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$23,014

Medicare's payments for the services billed

Medicare patients

85

Average age 58

Services billed

341

48 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 72%
High blood pressure 61%
Arthritis 42%
Diabetes 24%
COPD 21%
Ischemic heart disease 18%
Alzheimer's or dementia 16%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $916
$916 45 —
CAPLYTA
  • ITI, Inc. $437
$437 46 —
REXULTI
  • Lundbeck LLC $210
  • Otsuka America Pharmaceutical, Inc. $115
  • Otsuka Pharmaceutical Development & Commercialization, Inc. $20
$344 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $197
$197 — —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $176
$176 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

414 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record